Gallbladder cancer (GBC) is the most common cancer of the biliary tract, characterized by a
very poor prognosis when diagnosed at advanced stages owing to its aggressive behaviour …

Simple Summary Over the last decade, immune checkpoint inhibitors (ICIs) targeting
programmed death 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T …

Background: Immunotherapy has recently been incorporated into the spectrum of biliary tract
cancer (BTC) treatment. The identification of predictive response biomarkers is essential in …

Gallbladder cancer (GBC) is a rare, highly aggressive malignancy with a 5-year survival rate
of 5–10% in advanced cases, highlighting the need for more effective therapies. The aim of …

Simple Summary Knowledge of genetic alterations in gallbladder cancer (GBC) continues to
increase. This systematic review provides an overview of frequently occurring genetic …

Simple Summary Biliary tract cancers (BTCs) are a rare pathology. In the era of precision
oncology, the development of next-generation sequencing (NGS) allowed a better …

Simple Summary Gallbladder cancer (GBC) is the most common biliary tract cancer
worldwide, with incidental GBC being the most common presentation of resectable …

We developed and analytically validated a comprehensive genomic profiling (CGP) assay,
GEM ExTra, for patients with advanced solid tumors that uses Next Generation Sequencing …

Simple Summary Biliary tract cancers (BTCs) are rare tumors with devastating prognosis.
Gallbladder cancer (GBC) is the most common BTC, and even though recent advances have …

Background Targeted drugs are not quite effective for prolonging the survival of patients with
gastric cancer due to off-target effects as well as tumor immune escape mechanisms …